. The 53BP1-dependent pathway is also responsible for pathological joining events at dysfunctional telomeres 4 , and its unrestricted activity in Brca1-deficient cellular and tumour models causes genomic instability and oncogenesis [5] [6] [7] . Cells that lack core non-homologous end joining proteins are profoundly radiosensitive 8 , unlike 53BP1-deficient cells 9, 10 , which suggests that 53BP1 and its co-factors act on specific DNA substrates. Here we show that 53BP1 cooperates with its downstream effector protein REV7 to promote non-homologous end joining during class-switch recombination, but REV7 is not required for 53BP1-dependent V(D)J recombination. We identify shieldin-a four-subunit putative single-stranded DNA-binding complex comprising REV7, c20orf196 (SHLD1), FAM35A (SHLD2) and FLJ26957 (SHLD3)-as the factor that explains this specificity. Shieldin is essential for REV7-dependent DNA end-protection and non-homologous end joining during class-switch recombination, and supports toxic non-homologous end joining in Brca1-deficient cells, yet is dispensable for REV7-dependent interstrand cross-link repair. The 53BP1 pathway therefore comprises distinct double-strand break repair activities within chromatin and single-stranded DNA compartments, which explains both the immunological differences between 53bp1-and Rev7-deficient mice and the context specificity of the pathway.
, including REV7, which is a non-catalytic subunit of the translesion synthesis DNA polymerase-ζ. REV7 mediates genotoxic NHEJ events in Brca1-deficient mouse mammary tumour cells, and prevents end-resection at doublestrand breaks (DSBs) associated with class-switch recombination (CSR) 13 . We generated a conditional Rev7 knockout mouse (Rev7 f/f ) in a C57BL/6 background, after germline Rev7-deletion resulted in embryonic lethality (Extended Data Table 1 ). Rev7 f/f mice that possess the B cell Mb1-cre deleter allele 14 showed Rev7 deletion at the start of the B cell lineage (Extended Data Fig. 1a) , and normal B cell numbers with undetectable REV7 protein (Extended Data Fig. 1b) . Rev7
Mb1
+/cre mice expressed normal serum IgM but reduced titres of IgA and IgG, which is suggestive of CSR failure (Fig. 1a) . Defective in vivo CSR was confirmed in immunization experiments in which serum concentrations of antigen-specific IgG1 in Rev7
+/cre mice were about 10-fold lower than in control Rev7
+/cre mice, whereas IgM responses were comparable between groups (Fig. 1b) . Likewise, Rev7-deletion severely compromized-by up to 90%-the production of class-switched B splenocytes upon stimulation in culture ( 
+/cre double knockout cells furthermore confirmed REV7-53BP1 cooperation is essential for CSR (Fig. 1e) .
However, notable differences in the absolute numbers of B lineage cells were detected between Rev7 f/f Mb1 +/cre and 53bp1 −/− Mb1 +/cre mice ( Fig. 1f) . Though 53bp1-deficient mice showed 50% and 29% reductions in B220 + B lymphocytes in the bone marrow and spleen, respectively, these abnormalities were absent from Rev7
+/cre animals ( Fig. 1f) , leading us to question whether 53BP1-dependent DNA repair activities during B cell development require REV7. Detailed bone marrow analysis showed that B lymphocytes of 53bp1 
+/cre mice could be masked by compensatory changes, we generated chimaeric mice with mixed bone marrow cells. Equal mixes of CD45.1 wild-type and CD45. 
+/cre cells did not differ from that of wild-type CD45.1 cells, similar to that in control recipient mice (data not shown). However, bone marrow B cells derived from CD45.2 53bp1 −/− Mb1 +/cre mice only reconstituted about 30% of pro-B cell fractions, and were further outcompeted by wild-type CD45.1 bone marrow B cells at later stages, at which point they made up only about 15% of total immature and mature fractions (Extended Data Fig. 2e ). These findings confirmed that B cell development is normal in the absence of REV7, which suggests that V(D)J recombination-which is essential for this processdoes not require REV7.
To directly test whether 53BP1-dependent NHEJ during V(D)J recombination and CSR could be distinguished at the level of REV7 involvement, we monitored the stability of the Igh and Ig λ-light-chain ) mice. Upon stimulation with anti-CD40 plus IL-4 in vitro, NHEJ-deficient splenic B cells accumulate Igl breaks owing to abortive RAG1-and RAG2-dependent secondary V-J recombination events, as well as Igh breaks associated with CSR 15 . Chromosome breakage at Igh and Igl was monitored by four-colour Letter reSeArCH fluorescence in situ hybridization on metaphase spreads, using probes that were positioned centromeric and telomeric to these loci 15 .
Metaphases were classed as abnormal if either locus had bi-allelic centromeric BAC signals, with one allele lacking an adjacent signal from the telomeric BAC (Fig. 1h) . As expected, 53bp1 −/− B cells had high levels of chromosomal abnormalities at both the Igh and Igl loci, unlike control cells for which locus breakage was rare ( f P < 0.0001 P < 0.0001 P < 0.0001 +/+ Mb1 +/cre and Rev7 f/f Mb1 +/cre mouse cohorts. n = 11 mice per genotype; P values, unpaired two-tailed t-test. Mean ± 95% confidence interval. b, NP-specific serum IgM (left) and IgG1 (right) at indicated times after NP-CGG immunization. AU, arbitrary units. Representative data, n = 2 independent experiments, each with 4 mice. Mean ± 95% confidence interval. c, Cell trace violet (CTV)-labelled splenic B cells were stimulated as indicated and stained for surface IgG1 or IgE on day 4. Representative data, n > 6 mice. d, CTV dilution in purified B cells cultured in the presence of LPS and IL-4 for 96 h. Representative data, n > 6 mice. e, Splenic B cells cultured with the indicated stimuli (96 h) and stained for surface IgG1, IgE, IgG2b or IgG3. n = 4 mice per genotype. CSR 100%, mean immunoglobulin isotype switch frequency of 2 control animals in each experiment. P values, two-way ANOVA with Tukey's correction. Mean ± 95% confidence interval. f, Absolute numbers of B220 + B cells in the bone marrow (one femur plus one tibia) and spleen. n = 9 mice per genotype, except Rev7 
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consistent with a selective requirement for 53BP1 but not REV7 in V(D)J recombination.
To determine the function of REV7 in CSR, we deleted Rev7 in CH12-F3, a mouse B lymphoma cell line that undergoes efficient switching from IgM to IgA upon stimulation in vitro. CSR frequencies in Rev7 −/− CH12-F3 cells were increased approximately 10-fold by reconstitution of REV7 expression compared to a GST control (Fig. 2a) , and more than 20 REV7 single or combinatorial point mutants were screened for their ability to restore CSR ( Fig. 2b and Extended Data Fig. 3a, b) . Mutations that disrupt protein interactions 16, 17 , posttranslational modifications or a destruction-box degron 18 were selected, and structure-led conservation analysis guided the generation of mutants within putative protein-interaction surfaces (summarized in Extended Data Table 2 ). Stable CSR-defective REV7 mutants were re-tested for their ability to support CSR to IgG1 upon complementation in stimulated B cells from Rev7
Mb1
+/cre mice (Fig. 2c, d ). Two mutants, REV7(Y63A) and REV7(K129A), failed to rescue CSR to levels above those of control-complemented cells in both screens. The capacity of these mutants to prevent the hyper-resection of DSBs in the Igh switch region, which is a central function of the 53BP1-RIF1-REV7 axis during CSR 9, 11, 13, 19 , was therefore assessed by replication protein A (RPA)-single-stranded DNA (ssDNA) chromatin immunoprecipitation (ChIP) across Igh and control loci. As expected 13 , DSB-associated donor (Sμ) and acceptor (Sα) switch loci, but not non-targeted Igh (Sγ1) or control (Rpp30) loci, exhibited aberrant RPA-ssDNA enrichments in Rev7 −/− cells (Extended Data Fig. 3c ). RPA enrichments were suppressed in cell lines expressing wild-type REV7 but not the REV7(Y63A) or REV7(K129A) mutants, which confirms these mutations compromize resection inhibition (Extended Data Fig. 3c ).
REV7 Tyr63 is one of two evolutionarily conserved residues that mediate interactions between the C-terminal 'safety-belt' domain and two conserved REV7-binding motifs in REV3L (RBM 1 and RBM 2 ; consensus PxxxpPSR) 17, 20 , each of which is essential for REV3L-dependent resistance to interstrand cross-link damage 20 . Alanine substitutions at Tyr63 or Trp171 in REV7 blocked interactions with the RBM 1 of REV3L, in a yeast two-hybrid (Y2H) assay (Extended Data Fig. 4a ). As expected 21 
,

Rev7
−/− cells were sensitive to the interstrand cross-link inducer MMC, first accumulating in G2/M phase, and then progressing into cell death marked by an accumulation of sub-G1 events and profound chromosomal instability (Extended Data Fig. 4b-d) . These defects were completely suppressed by complementation with wildtype REV7 but not the REV7(Y63A) or REV7(W171A) mutants, or the REV1-binding mutants REV7(L186A) or REV7(Y202A) (Extended Data Fig. 4b, e) . By contrast, the CSR-deficient REV7(K129A) mutant completely restored wild-type responses to MMC, consistent with the unperturbed interaction between this mutant and REV3L (Extended Data Fig. 4a, e) . This separation of function between REV7 interstrand cross-link repair and NHEJ activities implicates distinct REV7 complexes in NHEJ.
We therefore immunopurified control and Flag-HA-REV7 complexes from lysates of stably complemented Rev7 −/− CH12-F3 cells, and analysed these by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Aside from the known interactors REV3L and GTF2I 22 , three uncharacterized proteins were highly enriched with REV7 ( Fig. 3a and Table 1 ). The genes that encode these proteins, c20orf196, FAM35A and FLJ26957 (also known as CTC-534A2.2)-renamed SHLD1, SHLD2 and SHLD3, respectively-were cloned and the corresponding human protein was screened for interaction with wild-type and mutant REV7 by Y2H. In this assay, only SHLD3 showed direct interaction with REV7; this was abolished by REV7(Y63A) but was unaffected by REV7(W171A) (Fig. 3b and Table 1 ), which correlates perfectly with the requirement for Tyr63 but not Trp171 in NHEJ. SHLD3 comprises two N-terminal REV3L-like RBM motifs, and predicted structural folds that resemble the mRNA cap-binding domain of the translational elongation initiation factor EIF4E ( Fig. 3c ; folds recognized by Phyre2 23 ). REV7-SHLD3 interactions rely predominantly on Pro53 and Pro58 in RBM 2 (Fig. 3c) , which is a motif that resembles RBM 1 in REV3L (Extended Data Fig. 5a ).
The CSR defects exhibited by REV7(K129A) could not be explained by a failure to interact with SHLD3 (Fig. 3b) . Lys129 is a highly 
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conserved residue on an uncharacterized structural surface that was selected upon analysis of the REV7 crystal structure 16 (Extended Data Fig. 5b) . A mutant containing a conservative arginine substitution of Lys129 completely restored wild-type CSR frequencies ( Fig. 2b and Extended Data Fig. 3b ), which eliminated consideration of posttranslational modification. Therefore, we compared the compositions of the Flag-HA-REV7(K129A) and wild-type Flag-HA-REV7 complexes using LC-MS/MS and label-free quantification (LFQ). Consistent with Y2H data, Flag-HA-REV7(K129A) complexes retained equivalent levels of REV3L and SHLD3 but were devoid of SHLD1-SHLD2 ( Fig. 3d and Table 1 ), implicating SHLD1 and SHLD2 in NHEJ.
Isogenic knockout CH12-F3 clones were therefore generated for Shld1, Shld2 and Shld3. No changes in REV7 or 53BP1 expression were identified in these knockout cell lines (Extended Data Fig. 6a ), which suggests a direct role for a complex formed by REV7 and all three SHLD proteins in NHEJ. Normal proliferation but diminished CSR was detected in all clones ( Fig. 6e ), confirming epistasis between Shld3 and Rev7 in NHEJ. These data indicate REV7 forms the linchpin in a four-subunit protein complex, the integrity of which is essential for 53BP1-dependent CSR. The C-terminal safety-belt of REV7 mediates interaction with SHLD3, and residues centred around Lys129 mediate binding to SHLD1-SHLD2 heterodimers. Structural modelling of SHLD2 revealed a tripletandem OB-fold architecture with structural homology to the core ssDNA-binding OB-folds 2-4 in fungal RPA70 24 (Extended Data Fig. 5c, d ). We and others 25 have named this putative ssDNA-binding complex 'shieldin' and its subunits as SHLD1, SHLD2 and SHLD3, by analogy with the telomere end-capping complex shelterin, the ssDNA and double-stranded DNA (dsDNA) binding proteins of which cooperate in chromosome end protection Interacting proteins were determined as in Fig. 3a, d . NA, not applicable; ND, not determined. n = 2 independent experiments. a Average log2(fold change(wild type/control)), n = 2. b Average log2(fold change(K129A/wild type)), n = 2.
Letter reSeArCH separation-of-function in interstrand cross-link repair and NHEJ (Extended Data Fig. 6h ).
We next investigated the contribution of shieldin to 53BP1-dependent toxic NHEJ in Brca1-deficient cells. CRISPR-Cas9-mediated mutagenesis of Shld3 in the Brca1
−/− mouse mammary tumour KB1P-G3 cell line 13 was strongly selected for in the presence of the poly(ADP-ribose) polymerase inhibitor (PARPi) olaparib (Extended Data Fig. 6i) . Moreover, PARPi resistance in Shld3 −/− KBP1-G3 cells was equivalent to Rev7 −/− KBP1-G3 controls (Fig. 4e, f) . There was neither selection for mutagenesis of Shld3 or Rev7 loci in olaparib-treated 53bp1 −/− KB1P-G3 cells, nor increased resistance in Shld3 −/− KB1P-G3 lines confirmed toxic NHEJ in Brca1-deficient cells is dependent on shieldin (Fig. 4g) . Shieldin disruption therefore provides a possible route to PARPi resistance in cancer.
This study reveals a requirement for a putative ssDNA-binding protein complex, shieldin, in the 53BP1 pathway, indicating that multiple DNA binding activities cooperate during DNA structure-specific NHEJ (Fig. 4h) . The coupling of 53BP1-dependent anti-resection activities within chromatin to shieldin-dependent stabilization of ssDNAtailed ends may permit the conversion of ssDNA-tailed substrates, such as those generated during CSR, into DSBs amenable to NHEJ. This segregation of distinct yet cooperative activities at DSB sites can explain the developmental differences between 53BP1-and REV7-deficient lymphocytes: ssDNA-tails of AID-dependent DSBs induced during CSR require these specialized activities to orchestrate their joining by NHEJ 27 , whereas the absence of ssDNA at RAG-induced DSBs produced during V(D)J recombination could preclude the need for shieldin. ssDNA-tailed DSBs additionally exist at uncapped telomeres, and potentially at collapsed replication forks, and thus a requirement for shieldin during the repair of these structures can explain the physiological and pathophysiological specificities of the 53BP1 system.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0362-1. 
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Per cent CSR to IgA (versus WT) −/− mice 9 suggests RIF1 could link 53BP1 anti-resection activities in chromatin to shieldin activities in ssDNA compartments (arrow).
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METhodS
Mice. All mice used for this study were generated on, or backcrossed onto a C57BL/6 background (>10 generations ) and related control mice were generated by intercrossing with mice containing the B cell lineage Mb1-cre deleter strain (Cd79a . All experiments involved age-matched 8-16-week-old animals on an inbred C57BL/6 background. 53bp1 −/− mice (MGI:2654201; also C57BL/6) were generated and described elsewhere 29 . For bone marrow mixed chimaera experiments, wild-type C57BL/6-Ly5.1 mice (hereafter known as CD45.1; Jax stock 002014) were irradiated with two doses of 4.5 Gy spaced 3 h apart, and subsequently injected with 5-10 × 10 6 bone marrow cells (approximately 50:50 mixture) of wild-type CD45.1 + bone marrow and either wild-type Mb1
Mb1
+/cre or 53bp1
) bone marrow. Baytril 10% antibiotic solution (Vet Services, University of Oxford) was added to drinking water (1.5 ml to 250 ml water) for 3 weeks after irradiation. Mice were allowed to reconstitute for 7-8 weeks before analysis. Sample sizes were determined by power calculations. We were not pursuing lower penetrance phenotypes, thus statistically significant data could typically be obtained with small group sizes (typically, 4-10 mice). 
+/cre mice were immunized intraperitoneally with 50 mg of NP-CGG (Santa Cruz Biotechnologies) emulsioned in Imject Alum adjuvant (Pierce, Thermo Fisher Scientific). Blood samples were collected from the tail vein at 0, 7, 14, 21 and 28 days after immunization. Enzyme-linked immunosorbent assays. Enzyme-linked immunosorbent assays (ELISAs) were used to quantify the production of NP-specific antibodies in mice serum. Ninety-six-well plates were coated with 1 μg/ml NP-BSA (Biosearch Technologies) in bicarbonate buffer, blocked with 5% milk in PBS and incubated with serial dilutions of serum collected at different time points from immunized mice. Plates were probed using alkaline phosphatase-coupled antibodies against mouse IgM and IgG1 (Southern Biotech). Phosphatase substrate (Sigma) was used for detection and optical density measured at 405 nm. For IgG1, pooled blood from post-immunization wild-type mice was used as a standard and serially diluted into a standard curve. The first dilution was established as 1,000 arbitrary units. For IgM pooled blood from day 7 was used as a standard. Immunoglobulin concentrations in mouse serum or culture supernatants were determined by sandwich ELISA. 5 per well in a 12-well plate) were cultured in RPMI supplemented with 10% FCS, 100 U/ml penicillin, 100 ng/ml streptomycin, 2 mM l-glutamine, 1× MEM nonessential amino acids, 1 mM sodium pyruvate and 50 μM β-mercaptoethanol. B cells were stimulated with 5 μg/ml LPS (Sigma, L7770-1MG), 10 ng/ml mouse recombinant IL-4 (Peprotech, 214-14-20), and agonist anti-CD40 antibody (0.5 μg/ml; Miltenyi Biotec; FGK45.5). Cultures were grown at 37 °C with 5% CO 2 under ambient oxygen conditions. Four days after seeding, stimulated B cells were analysed using a FACSCanto; analysis was performed using FlowJo. Cells were resuspended in FACS buffer, blocked with Mouse BD Fc Block, and immunostained with biotinylated antibodies as follows: anti-mouse IgG1 (1:100, BD Pharmingen 553441; A85-1), anti-mouse IgG2b (1:100, BioLegend 406704; RMG2b-1), anti-mouse IgG3 (1:100, BD Pharmingen 553401; R40-82) and Streptavidin APC (1:500, Thermo Fisher 17-4317-82). Cells expressing IgE were assessed using anti-Mouse IgE PE (1:200, BioLegend, 406908; RME-1). Live/ dead cells were discriminated after staining with Zombie Aqua viability dye. Cell proliferation was assessed using Cell Trace Violet according to manufacturer's instructions (CellTrace, Life Technologies). Primary B cell reconstitution. Mature untouched B cells were purified as above and stimulated with LPS (5 μg/ml, Sigma, L7770) and mouse recombinant IL-4 (10 ng/ml, Peprotech, 214-14-20). Cultures were grown at 37 °C with 5% CO 2 under ambient oxygen conditions. Filtered retroviral supernatants, collected 48 h after co-transfection of BOSC23 cells with 7 μg pCL-Eco and 7 μg pMX-IRES-GFP-derived plasmids, were used to infect LPS/IL-4-stimulated B cell cultures in the presence of polybrene (2.5 μg/ml) and HEPES (20 mM) by spinoculation (850g for 90 min at 30 °C). After a rest period of 4 to 6 h, viral supernatants were removed, and replaced with LPS/IL-4-supplemented culture medium. Three days later, surface IgG1 expression was determined in populations of gated cells that were positive for the expression of an eGFP retroviral reporter. CH12-F3 cell culture and CRISPR-Cas9 editing. All CH12-F3 cell lines were cultured in RPMI supplemented with 5% NCTC-109 medium, 10% FCS, 100 U/ml penicillin, 100 ng/ml streptomycin and 2 mM l-glutamine at 37 °C with 5% CO 2 under ambient oxygen conditions. Rev7
) and Flj26957 (Shld3 −/− ) CH12-F3 were generated using CRISPR-Cas9. In brief, gene-specific sgRNAs (sgRNA sequences in Extended Data Table 3a) were cloned in modified pX330 (Addgene #42230) or pX458 vectors (Addgene #48138). CH12-F3 cells were nucleofected (Amaxa Nucleofector 2b, Lonza) with 2 μg of plasmid and Cell Line Nucleofector Kit R (Lonza), using program D-023. Isogenic cell clones were isolated by limiting dilution (pX330) or GFP sorting (pX458) single cell into 96-well plates. Clones bearing bi-allelic indel mutations were identified by native PAGE resolution of PCR amplicons corresponding to edited loci (amplicon primer sequences in Extended Data Table 4b ), and gene disruption subsequently confirmed by Sanger sequencing (sequencing results in Extended Data Table 3b ). Where antibodies were available, effective target protein ablation was confirmed by immunoblotting. Complemented cell lines were generated by lentivirus-mediated transduction, using viral supernatants collected from 293T cells co-transfected with third generation packaging vectors and pLenti-PGK-PURO-DEST (Addgene #19068) or pLenti-PGK-Flag-HA-PURO-DEST vectors containing cloned transgene inserts. Typically, cells were spinoculated with polybrene (8 μg/ml) and HEPES (20 mM)-supplemented viral supernatants (1500 rpm, 90 min at 25 °C). Stable cell-lines were subsequently selected and maintained in the presence of puromycin (1 μg/ml). To stimulate CSR to IgA, CH12-F3 cells were stimulated with agonist anti-CD40 antibody (0.5 μg/ml; Miltenyi Biotec; FGK45.5), mouse IL-4 (5 ng/μl; R&D Systems) and TGFβ1 (2.5 ng/μl; R&D Systems). Cell-surface IgA expression was determined by flow cytometric staining with anti-mouse IgA-FITC antibody (Thermo Fisher; 11-4204-82; MA-6E1). CH12-F3 proliferation was monitored by dye dilution using carboxyfluorescein succinimidyl ester (CFSE) according to manufacturer's instructions (CellTrace; Life Technologies). In cell cycle experiments, CH12-F3 cells pulse-treated with BrdU for 30 min before fixation in 70% ethanol were stained with propidium iodide and rat anti-BrdU-FITC (1:100, Bio-Rad MCA2060FT). Certified mycoplasma free CH12-F3 were obtained by Cell Services (Francis Crick Institute). These and other cell lines (for example, 293T, BOSC-23) were confirmed free of mycoplasma contamination. Antibodies. Immunoblot primary antibodies used in this study; anti-Rif1: Clone SK1316; gift of Ian Adams 30 ; anti-histone H3: Abcam ab10799, clone 10799; 1:2,000; anti-Rev7: BD 612266, clone 14/MAD2B/Rev7, 1:500; anti-53BP1: Novus Biologicals NB100-304, 1:2,500; anti-HA-11: BioLegend 901501, Clone 16B12, 1:2,000; anti-actin: Sigma A1978, Clone AC15, 1:2,000; anti-tubulin: Sigma 00020911, Clone TAT-1, 1:10,000. Proteins were detected using HRP-conjugated secondary antibodies (α-rabbit, Thermo Fisher 31462, 1:50,000; anti-mouse, Thermo Fisher 31432, 1:50,000; Mouse TrueBlot ULTRA, Rockland 18-8817-33, 1:5000) and enhanced chemiluminescence (Clarity, Bio-Rad). Signals were acquired digitally on a Gel Doc XR system (Bio-Rad). Proteomics and mass spectrometry. Pellets collected from cultures of ~4 × 10 7 CH12-F3 cells were lysed in BLB (Benzonase Lysis buffer: 20 mM HEPES pH 7.9, 40 mM KCl, 2 mM MgCl 2 , 10% glycerol, 0.5% NP40, 50 U/ml Benzonase (Novagen), 0.05% (v/v) phosphatase inhibitors (Sigma-Aldrich) and protease
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inhibitors (Complete EDTA-free, Roche)) and were incubated on ice for 30 min before a second incubation with adjusted salt (450 mM KCl). Flag-REV7 or control complexes were isolated from clarified lysates, following their dilution in NSB (no-salt buffer: 20 mM HEPES (pH 7.9), 10% glycerol, 0.5 mM DTT, 0.5 mM EDTA, 0.05% (v/v) phosphatase inhibitors (Sigma-Aldrich) and protease inhibitors (Roche)) to a final salt concentration of 125 mM. Flag-HA-REV7 complexes were immunopurified on anti-Flag (M2) magnetic resin (Sigma-Aldrich), washed extensively in wash buffer (BLB supplemented with 125 mM KCl and 0.1% NP-40) and eluted with 3 × Flag peptide (Sigma-Aldrich). Flag-peptide eluted complexes were reduced and alkylated using DTT and iodoacetamide, followed by a chloroform/ methanol precipitation. Proteins were resuspended in 6 M urea and digested over night with trypsin (Promega). Peptides were desalted (Sola, Thermo) and analysed on a LC-MS platform consisting of a Dionex Ultimate 3000 nHPLC and Q-Exactive mass spectrometer. Peptides were separated on an EASY-Spray column (50 cm, ES803, Thermo) with a gradient of 3-35% acetonitrile in 5% DMSO and 0.1% formic acid at 250 nl/min. MS1 spectra were acquired at a resolution of 70,000 at 200 m/z. Up to the 15 most abundant precursor ions were selected for subsequent MS/MS analysis after ion isolation with a mass window of 1.6 Th. Peptides were fragmented by HCD with 28% collision energy. Progenesis QI (v.3, Waters) was used for spectral counting and LFQ of the LC-MS/MS data with default parameters (top 3 quantitation mode). Proteins were identified with PEAKS 8.0 (Bioinformatics Solutions) using standard parameters and the Uniprot mouse reviewed proteome (retrieved 28 November 2017). Peptide false discovery rate (FDR) was set to 1% with a resulting protein FDR of 1.88%. Chromatin immunoprecipitation. Each ChIP was performed from chromatin prepared from ~10 7 CH12-F3 cells stimulated for 30 h with agonist CD40 antibody, IL-4, and TGFβ1 as previously described 13 . Each ChIP was performed using 30-50 μg CH12-F3 chromatin using RPA34-20 (3 μg; Ab-3, Calbiochem) or anti-histone H3 (2 μg; ab1791, Abcam) coupled to 25 μl protein G Dynabeads (Life Technologies, 10003D). Relative quantities of ChIP-enriched DNA were calculated relative to total input chromatin by qPCR in triplicate on CFX96 Real-Time Analyzer (Bio-Rad) or StepOnePlus (Applied Biosystems) instruments using Quantifast SYBR Green reagent (Qiagen) and locus-specific primer pairs (Extended Data Table 4a ). Yeast two-hybrid interaction. Open reading frames encoding the indicated proteins were cloned into pAD-DEST and pBD-DEST vectors and transformed into Saccharomyces cerevisiae (strain PJ69-4A). Ten-millilitre cultures prepared from single transformants were diluted to equal volumes containing 2 × 10 7 cells, and fivefold serial dilutions 'spotted' on control (−Leu, −Trp) or experimental (−Leu, −Trp, −His) plates supplemented with 3-amino-1,2,4-triazole (3-AT, 6 mM, Sigma A8056). Plates were incubated at 30 °C for 3 days.
PARPi resistance. KB1P-G3 and 53bp1
−/− KB1P-G3 cells were infected with viral supernatant generated using lentiCRISPR-Bsr. Following selection in blasticidin (10 mg/ml), genomic DNA (gDNA) samples were collected immediately before seeding for olaparib sensitivity. Blasticidin-resistant populations were seeded in 6-well plates at a density of 10 4 cells per well (5 × 10 3 for 53bp1 −/− KB1P-G3) in the presence of olaparib or DMSO and grown at 37 °C (5% CO 2 and 3% O 2 ). Medium was refreshed at 4 days and 8 days. After 10 days, cultures were expanded in fresh medium for 1 week in 6-cm dishes before collecting gDNA. PCR amplicons encompassing the edited locus were PCR amplified from gDNA, Sanger sequenced (GATC Biotech) and analysed by tracking of indels by decomposition (https://tide. deskgen.com/). Surviving cells were collected and three replicates were plated in DMSO and three in olaparib for viability analysis. DMSO and olaparib-treated cells were stained with crystal violet (0.5% (w/v) crystal violet in 25% methanol) after 8 days and 10 days growth (37 °C, 5% CO 2 and 3% O 2 ), respectively. Crystal violet stained cells were dissolved in a 10% (v/v) acetic acid solution a minimum of 24 h after staining and the OD 595 was measured as a quantitative metric of relative growth. In Fig. 4g , cells were incubated for 24 h in olaparib 250 nM in standard medium, before metaphase chromosomes were collected. Cytological analysis. Metaphase spreads were prepared by standard methods. In brief, detached cells were resuspended in KCl 75 mM for 20 min, before being fixed in Carnoy's fixative. Approximately 20 μl of cell suspension was dropped onto clean slides and left to dry overnight. The cells were then stained with propidium iodide 0.5μg/ml in PBS for 20 min, rinsed and the slides mounted in Vectashield/DAPI (Vector Labs). The slides were analysed blind, and a minimum of 50 metaphases were acquired using an Olympus BX60 microscope for epifluorescence equipped with a Sensys CCD camera (Photometrics). Images were collected using Genus Cytovision software (Leica). Fluorescence in situ hybridization analysis. BAC probes (RP23-41J14 (Igh 3ʹ); RP24-316H6 (Igh 5ʹ) (gifts from the Welcome Sanger Institute, Hinxton); RP23-374P12 (Igl 3ʹ); RP23-382P9 (Igl 5ʹ) (Source Bioscience)) were labelled using a nick translation kit (Abbott Molecular) according to the manufacturer's instructions, incorporating either Chromatide Alexa Fluor 594-5-dUTP (Thermo Fisher Scientific), Chromatide Alexa Fluor 488-5-dUTP (Thermo Fisher Scientific), Gold-dUTP (Abbott Molecular) or biotin-16-dUTP (Sigma). The probes were resuspended in the presence of a ten-times excess of unlabelled mouse C0t1 DNA (Thermo Fisher Scientific), in hybridization buffer (50% formamide, 10% dextran sulphate, 2×SSC), before being denatured for 8 min at 85 °C, followed by a pre-annealing step 30 min at 37 °C. The metaphase spreads were denatured in 0.07 N NaOH for 1 min. The probes were applied onto the slides, and the hybridization was carried out overnight at 37 °C. Three post-hybridization washes were performed, in 0.1× SSC buffer at 65 °C. Biotinylated probes were detected using streptavidin-Cy5 (Thermo Fisher Scientific). Slides were mounted in Vectashield/ DAPI and analysed blind with the microscope described above. Between 98 and 150 metaphases were analysed for each mouse with the exception of one case (45 metaphases collected for one control mouse). Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability statement. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository, with the dataset identifier PXD009650 (https://doi.org/10.6019/PXD009650). Letter reSeArCH 
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Extended Data Fig. 2 | B cell lineage developmental differences in  Rev7-and 53bp1-deficient mice. a, Flow cytometry analysis 
Extended data All studies must disclose on these points even when the disclosure is negative.
Sample size
For mouse experiments, sample sizes were determined by power calculations. We were not pursuing lower penetrance phenotypes, thus statistically significant data could typically be obtained with 4-6 mice per group (age matched mice of a single genotype), plotted with 95% CI and statistical significance of phenotype-specific differences determined by unpaired students t-test.
Data exclusions No data was excluded from the study
Replication
Following extensive optimization, biological experiments were typically performed in 2-3 biological replicates (each performed identically on different days). In the majority of cases, each biological replicate (e.g. clonogenic assay, flow cytometric sample or ChIP amplicon) involved 3 technical replicates. To ensure reproducibility of immunization experiments, antigen-specific immune responses in each group: Rev7+/+ Mb1 +/Cre (n=4), REV7 F/F Mb1+/Cre (n=4), WT (n=2) and WT (No Cre_ non-immunised (n=2); were analyzed in two independent experiments, each yielding equivalent genotype-specific responses. For B cell lineage developmental staging, 2-3 age-matched mice per genotype were analysed in each experiment (total 4 experiments), each resulting in equivalent results (data presented is pooled results from 4 experiments). Experiments using CRISPR-Cas9 edited cell-lines: as shown throughout the manuscript, genotype specific phenotypes were revalidated across multiple independently generated knockout cells lines (n>3 per guide-RNA).
Randomization Randomization of samples was only undertaken to remove potential biases during the scoring of chromosomal aberration during metaphase analyses. During animal experiments, mice of a certain genotype were typically selected based on a unique mouse ID# that does not indicate mouse genotype, thus phenotype-genotype relationships were determined only at the data analysis stage. In some cases, (e.g. 53BP1-/-, phenotype was clearly apparent even at the tissue harvesting stage due to a 50% reduction in lymphocyte recovery). Each experiment involving mice involved comparing n>=2 mice per genotype in a single experiment, with the experiment being repeated at least twice, and typically 3 times. Age-matched mice were used as a method to control for covariates.
Blinding
Randomization of samples and blind analysis was only undertaken to remove potential biases during the scoring of chromosomal aberration during metaphase analyses.
Reporting for specific materials, systems and methods Yes -we maintain a very strict regime of mycoplasma testing, and no cell-line tested positive.
Commonly misidentified lines (See ICLAC register)
We have checked the ICLAC register and the cell lines we used in our studies are not on the list of misidentified cell lines.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals All mice were generated or backcrossed (>10 generations) on a pure C57BL/6 background. All experiments were carried out under Home Office (HO) License regulations. Both male and female animals were used in the study. The PI has a UK HO approved project licence (P070A7B02), which comprised of all necessary protocols required to undertake the research outlined in the manuscript. Experiments were also undertaken in compliance with local University and ethical guidelines. Mice were aged 8-16 weeks.
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
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